Caribou Biosciences' vispa-cel, a Phase 3-ready allogeneic CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, has a Food and Drug Administration-agreed pivotal Phase 3 trial design.

Health news, debates, and claims covering public health, mental health, nutrition, medical care, and health policy.

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.

Cancer treatment modalities including targeted therapy, immunotherapy, biologic therapies, and AI-driven treatment approaches.

Blood cancers and hematologic malignancies including leukemia, lymphoma, and related disorders.